A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1999 participants.

Also called NCT01715818

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,999 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01715818
  • EudraCT 2012-000671-16
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Austria, Canada, Chile, Colombia, Czechia, Estonia, Germany, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Poland, Romania, Russia, South Africa, South Korea, Spain, Sweden, Thailand, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01715818. Randomized; double masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2013-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Condition
Cardiovascular Disease, Diabetes Mellitus Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
aleglitazar
Lead sponsor
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct01715818
Content hash
eec8d0dcc00da535f1bdacc4dfaa6416b9484910dfd5d4e1f6b49bf581f47119